FrancophonIA/ELRC3.0 huggingface dataset:
English: Respiratory, thoracic and mediastinal disorders Uncommon: Rare:
Croatian: Poremećaji dišnog sustava, prsišta i sredoprsja Manje često:
English: How to store Zoledronic acid medac
Croatian: Kako primjenjivati Zoledronatnu kiselinu medac
English: Uveitis
Croatian: Pamidronat
English: Multiple event analysis showed a 36 % risk reduction in developing SREs in the zoledronic acid 4 mg group compared with placebo.
Croatian: Analiza višestrukih događaja pokazala je smanjenje rizika od nastanka koštanih događaja za 36% u skupini koja je primala zoledronatnu kiselinu u dozi od 4 mg u odnosu na placebo.
English: In post-marketing experience, severe and occasionally incapacitating bone, joint, and/or muscle pain have been reported in patients taking bisphosphonates, including zoledronic acid.
Croatian: U razdoblju nakon stavljanja lijeka u promet, u bolesnika koji su uzimali bisfosfonate, uključujući zoledronatnu kiselinu, zabilježeni su jaki i ponekad onesposobljavajući bolovi u kostima, zglobovima i/ili mišićima.
English: Zoledronic acid medac 4mg/100ml solution for infusion medac Gesellschaft für klinische Spezialpräparate mbH Theaterstr.
Croatian: PROIZVOĐAČI ODGOVORNI ZA PUŠTANJE SERIJE LIJEKA U PROMET Naziv i adrese proizvođača odgovornih za puštanje serije lijeka u promet Zoledronatna kiselina medac 4 mg/100 ml otopina za infuziju medac Gesellschaft für klinische Spezialpräparate mbH Theaterstr.
English: LABEL ON MULTIPACKS WITH 10 BOTTLES WRAPPED IN TRANSPARENT FOIL (INCLUDING BLUE BOX)
Croatian: NALJEPNICA NA VIŠESTRUKOM PAKIRANJU S 10 BOCA OMOTANOM PROZIRNOM FOLIJOM (UKLJUČUJUĆI PLAVI OKVIR)
English: How Zoledronic acid medac is used
Croatian: Kako se daje Zoledronatna kiselina medac
English: QUALITATIVE AND QUANTITATIVE COMPOSITION One bottle with 100 ml solution contains 4 mg zoledronic acid (as monohydrate).
Croatian: Jedna boca sa 100 ml otopine sadrži 4 mg zoledronatne kiseline (u obliku hidrata).
English: Manufacturer Sanochemia Pharmazeutika AG
Croatian: Sanochemia Pharmazeutika AG Landegger Straße 7
English: Hypocalcaemia has been reported in patients treated with zoledronic acid.
Croatian: U bolesnika liječenih zoledronatnom kiselinom zabilježena je hipokalcemija.
English: - High blood pressure, shortness of breath, dizziness, sleep disturbances, taste disturbances,
Croatian: - bol u prsištu - kožne reakcije (crvenilo i oticanje) na mjestu primjene infuzije, osip, svrbež - visok krvni tlak, nedostatak zraka, omaglica, poremećaji spavanja, promjena osjeta okusa,
English: If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2 °C - 8 °C, unless dilution has taken place in controlled and validated aseptic conditions.
Croatian: Ako se ne primijeni odmah, vrijeme i uvjeti čuvanja prije primjene odgovornost su korisnika i ne bi trebali biti dulji od 24 sata na temperaturi od 2°C - 8°C, osim ako se razrjeđivanje provelo u kontroliranim i validiranim aseptičkim uvjetima.
English: trembling, tingling or numbness of the hands or feet, diarrhoea, abdominal pain, dry mouth.
Croatian: drhtavica, trnci ili utrnulost šaka ili stopala, proljev, bol u trbuhu, suha usta - nizak broj bijelih krvnih stanica i krvnih pločica
English: NAME OF THE MEDICINAL PRODUCT Zoledronic acid medac 4 mg/100 ml solution for infusion Zoledronic acid
Croatian: Zoledronatna kiselina medac 4 mg/100 ml otopina za infuziju zoledronatna kiselina
English: In clinical trials with zoledronic acid, patients with serum creatinine > 265 µmol/l or > 3.0 mg/dl were excluded.
Croatian: Bolesnici s vrijednošću kreatinina u serumu većom od 265 μmol/l ili 3,0 mg/dl bili su isključeni iz kliničkih ispitivanja zoledronatne kiseline.
English: NAME OF THE MEDICINAL PRODUCT Zoledronic acid medac 4 mg/100 ml solution for infusion
Croatian: Zoledronatna kiselina medac 4 mg/100 ml otopina za infuziju
English: Rare (may affect up to 1 in 1,000 people): - Slow heart beat.
Croatian: Rijetko (mogu se javiti u do 1 na 1000 osoba):
English: NAME OF THE MEDICINAL PRODUCT Zoledronic acid medac 4 mg/5 ml concentrate for solution for infusion
Croatian: Zoledronatna kiselina medac 4 mg/5 ml koncentrat za otopinu za infuziju
English: Zoledronic acid medac is supplied as packs containing 1 bottle or multipacks of 4 or 10 cartons each containing 1 bottle.
Croatian: Zoledronatna kiselina medac isporučuje se u pakiranjima koja sadrže 1 bocu ili višestrukim pakiranjima s 4 ili 10 kutija od kojih svaka sadrži 1 bocu.
English: NAME OF THE MEDICINAL PRODUCT Zoledronic acid medac 4 mg/5 ml concentrate for solution for infusion Zoledronic acid
Croatian: Zoledronatna kiselina medac 4 mg/5 ml koncentrat za otopinu za infuziju zoledronatna kiselina
English: How much Zoledronic acid medac is given - The usual single dose given is 4 mg. - If you have a kidney problem, your doctor will give you a lower dose depending on the severity of your kidney problem.
Croatian: Koliko se Zoledronatne kiseline medac daje - Obično se daje jednokratna doza od 4 mg.
English: LABEL ON MULTIPACKS WITH 10 VIALS WRAPPED IN TRANSPARENT FOIL (INCLUDING BLUE BOX)
Croatian: NALJEPNICA NA VIŠESTRUKOM PAKIRANJU S 10 BOČICA OMOTANOM PROZIRNOM FOLIJOM (UKLJUČUJUĆI PLAVI OKVIR)
English: Muscle spasms, osteonecrosis of the jaw Osteonecrosis of the external auditory canal (bisphosphonate class adverse reaction) and other anatomical sites including femur and hip
Croatian: (nuspojava razreda bisfosfonata) i drugih anatomskih mjesta uključujući bedrenu kost i kuk
English: While being treated with Zoledronic acid medac, you should maintain good oral hygiene (including regular teeth brushing) and receive routine dental check-ups.
Croatian: Za vrijeme liječenja Zoledronatnom kiselinom medac morate održavati dobru higijenu usne šupljine
English: If you are given more Zoledronic acid medac than you should be If you have received doses higher than those recommended, you must be carefully monitored by your doctor.
Croatian: Što morate znati prije nego primite Zoledronatnu kiselinu medac Pažljivo slijedite sve upute koje ste dobili od liječnika.
English: Uncommon (may affect up to 1 in 100 people): - Hypersensitivity reactions.
Croatian: Manje često (mogu se javiti u do 1 na 100 osoba):
English: NA Not applicable
Croatian: NP Nije primjenjivo.
English: Zoledronic acid medac is supplied as packs containing 1 bottle or multipacks of 4 or 10 packs each containing 1 bottle.
Croatian: Zoledronatna kiselina medac isporučuje se u pakiranjima od 1 boce ili višestrukim pakiranjima od 4 ili 10 pakiranja od kojih svako sadrži 1 bocu.
English: EXP.
Croatian: NP
English: METHOD OF ADMINSTRATION Dilute before use.
Croatian: Razrijediti prije primjene.
English: - Low level of magnesium and potassium in the blood.
Croatian: - niska razina magnezija i kalija u krvi; liječnik će pratiti ove elektrolite i poduzeti potrebne mjere
English: MARKETING AUTHORISATION NUMBER EU/1/12/779/004
Croatian: BROJ(EVI) ODOBRENJA ZA STAVLJANJE LIJEKA U PROMET EU/1/12/779/004
English: MARKETING AUTHORISATION NUMBER(S) EU/1/12/779/005
Croatian: BROJ(EVI) ODOBRENJA ZA STAVLJANJE LIJEKA U PROMET EU/1/12/779/005
English: How to prepare and administer Zoledronic acid medac
Croatian: Kako čuvati Zoledronatnu kiselinu medac
English: MARKETING AUTHORISATION NUMBER(S) EU/1/12/779/002
Croatian: BROJ(EVI) ODOBRENJA ZA STAVLJANJE LIJEKA U PROMET EU/1/12/779/002
English: Zoledronic acid medac 4 mg/5 ml concentrate for solution for infusion, further diluted in 100 ml (see section 6.6), should be given as a single intravenous infusion in no less than 15 minutes.
Croatian: 100 ml (vidjeti dio 6.6), treba dati kao jednokratnu intravensku infuziju u trajanju od najmanje 15 minuta.
English: 6.3 Shelf life
Croatian: ND ND ND 640
English: - Urticaria.
Croatian: U venu.
English: Any SRE (+TIH)
Croatian: (N=90)
English: 0.5 mg/dl or 44 µmol/l;
Croatian: 9 mg/ml (0,9%), ili 5%
English: EXP: Read the leaflet for the shelf life of the medicinal product after first opening.
Croatian: Za rok valjanosti lijeka nakon prvog otvaranja pročitajte uputu o lijeku.
English: TIH:
Croatian: NN:
English: Sodium citrate Water for injections
Croatian: otopine glukoze za injekciju (ml)
English: In view of the potential impact of zoledronic acid on renal function, the lack of clinical safety data in patients with severe renal impairment (in clinical trials defined as serum creatinine ≥ 400 µmol/l or
Croatian: S obzirom na mogući utjecaj bisfosfonata, uključujući i zoledronatnu kiselinu, na funkciju bubrega, nedostatak kliničkih podataka o sigurnosti primjene u bolesnika s teškim oštećenjem funkcije bubrega (u kliničkim ispitivanjima definiranim kao kreatinin u serumu ≥ 400 μmol/l ili ≥ 4,5 mg/dl u bolesnika s hiperkalcemijom izazvanom tumorom odnosno ≥ 265 μmol/l ili ≥ 3,0 mg/dl u bolesnika s rakom i metastazama u kostima) na početku liječenja i ograničene farmakokinetičke podatke u bolesnika s teškim oštećenjem funkcije bubrega (klirens kreatinina < 30 ml/min) na početku liječenja, ne preporučuje se primjena zoledronatne kiseline u bolesnika s teškim oštećenjem funkcije bubrega.
English: You should not be given Zoledronic acid medac if you are pregnant.
Croatian: Ako ste trudni, ne smijete primati Zoledronatnu kiselinu medac.
English: Zoledronic acid 8 mg (N=90)
Croatian: Zoledronatna kiselina 8 mg
English: MA (EU) number (Invented) name Strength Pharmaceutical Form Route of Administration Immediate Packaging Pack size
Croatian: (Zaštićeno) ime Doza Farmaceutski oblik Put primjene
English: Further information on Lemtrada can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/lemtrada
Croatian: Više informacija o lijeku Lemtrada dostupno je na internetskim stranicama Agencije: ema.europa.eu/medicines/human/EPAR/lemtrada
English: 1 See outcome of safety review carried out in 2019.
Croatian: 1 Pogledajte ishod sigurnosnog pregleda provedenog 2019..
English: Lemtrada is given as an infusion (drip) into a vein over about 4 hours.
Croatian: Lemtrada se primjenjuje intravenskom infuzijom (ukapavanjem) u venu u trajanju od oko četiri sata.
English: What is Lemtrada and what is it used for?
Croatian: Što je Lemtrada i za što se koristi?
English: What measures are being taken to ensure the safe and effective use of Lemtrada?
Croatian: Koje se mjere poduzimaju kako bi se osigurala sigurna i učinkovita primjena lijeka Lemtrada?
English: CD52 is found on lymphocytes, white blood cells that are part of the immune system.
Croatian: CD52 se nalazi na limfocitima, bijelim krvnim stanicama koje su dio imunosnog sustava.
English: Lemtrada received a marketing authorisation valid throughout the EU on 12 September 2013.
Croatian: Lijek Lemtrada dobio je odobrenje za stavljanje u promet koje je na snazi u EU-u od 12. rujna 2013.
English: The Agency considered that studies have shown the benefit for patients with highly active disease and rapidly worsening severe disease.
Croatian: Agencija je smatrala da su ispitivanja pokazala koristi za bolesnike kod kojih je bolest teška, vrlo aktivna i brzo se pogoršava.
English: The way alemtuzumab acts in multiple sclerosis is not fully understood, but it is believed that its effect on lymphocytes reduces the immune system's damaging activity.
Croatian: Način djelovanja alemtuzumaba na multiplu sklerozu nije u potpunosti poznat, no smatra se da njegov učinak na limfocite smanjuje štetnu aktivnost imunosnog sustava.
English: Other information about Lemtrada
Croatian: Ostale informacije o lijeku Lemtrada
English: • disease that is highly active, even though they have been treated with a disease-modifying therapy;
Croatian: • kod kojih je bolest izrazito aktivna, iako su prošli terapiju koja modificira tijek bolesti;
English: Patients should receive certain medicines before or during treatment to reduce the side effects.
Croatian: Bolesnici trebaju primiti određene lijekove prije ili tijekom terapije za smanjenje nuspojava.
English: Lemtrada is used for patients with:
Croatian: Lemtrada se koristi u bolesnika:
English: The European Medicines Agency decided that Lemtrada's benefits are greater than its risks and it can be authorised for use in the EU.
Croatian: Europska agencija za lijekove zaključila je da koristi od lijeka Lemtrada nadmašuju s njim povezane rizike te da može biti odobren za primjenu u EU-u.
English: • rapidly worsening, severe disease, who have had 2 or more relapses in one year and whose brain scans show certain brain lesions.
Croatian: • s teškim oblikom bolesti koja brzo napreduje, koji su iskusili dva ili više relapsa u jednoj godini i kod kojih snimke mozga pokazuju određene lezije na mozgu.
English: As for all medicines, data on the use of Lemtrada are continuously monitored.
Croatian: Kao i za sve lijekove, podatci o primjeni lijeka Lemtrada kontinuirano se prate.
English: What are the risks associated with Lemtrada?
Croatian: Koji su rizici povezani s lijekom Lemtrada?
English: Lemtrada can only be obtained with a prescription.
Croatian: Lemtrada se izdaje samo na recept.
English: The company will ensure that doctors expected to prescribe the medicine receive educational materials containing important safety information, and a checklist covering the necessary screening, medicines to reduce side effects, monitoring before, during and after infusion, and long-term monitoring of patients.
Croatian: Tvrtka će osigurati da liječnici za koje se očekuje da će propisivati lijek dobe materijale za obuku sa važnim informacijama o sigurnosti lijeka te kontrolni popis koji obuhvaća nužna snimanja, lijekove za ublažavanje nuspojava, praćenje prije, tijekom i nakon infuzije te dugoročno praćenje bolesnika.
English: Over half of patients included in the extension study did not have disease progression and did not need additional Lemtrada infusions.
Croatian: U više od polovice bolesnika uključenih u produžetak ispitivanja nije došlo do progresije bolesti te nisu trebali dodatne infuzije lijeka Lemtrada.
English: For those patients who needed one or two additional infusions with Lemtrada, the number of relapses was lower, and disability progression was slower, compared with the previous year.
Croatian: U bolesnika koji su morali primiti jednu ili dvije dodatne infuzije lijeka Lemtrada, broj relapsa bio je manji, a progresija invaliditeta sporija u usporedbi s prethodnom godinom.
English: It is initially given in two courses of treatment: a first course of 12 mg daily for 5 days, followed 12 months later by a second course of 12 mg daily for 3 days.
Croatian: Inicijalno se daje u dva ciklusa liječenja: prvi ciklus iznosi 12 mg na dan tijekom pet dana, nakon čega 12 mjeseci kasnije slijedi drugi ciklus od 12 mg na dan tijekom tri dana.
English: Up to two additional courses, each of 12 mg daily for 3 days, can be given at 12-month intervals.
Croatian: Do dva dodatna ciklusa liječenja od 12 mg na dan tijekom tri dana mogu se primijeniti u intervalima od 12 mjeseci.
English: Side effects reported with Lemtrada are carefully evaluated and any necessary action taken to protect patients.
Croatian: Nuspojave prijavljene za lijek Lemtrada pažljivo se procjenjuju i poduzimaju se potrebne mjere za zaštitu bolesnika.
English: An overview of Lemtrada and why it is authorised in the EU
Croatian: Pregled informacija o lijeku Lemtrada i zašto je odobren u EU-u
English: Lemtrada has been studied in two main studies involving 1,421 patients with relapsing-remitting multiple sclerosis.
Croatian: Lijek Lemtrada ispitivan je u dvama glavnim ispitivanjima koja su obuhvatila 1 421 bolesnika s relapsno-remitirajućom multiplom sklerozom.
English: Why is Lemtrada authorised in the EU?
Croatian: Zašto je lijek Lemtrada odobren u EU-u?
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Lemtrada have also been included in the summary of product characteristics and the package leaflet.
Croatian: Preporuke i mjere opreza kojih se zdravstveni radnici i bolesnici trebaju pridržavati u cilju sigurne i učinkovite primjene lijeka Lemtrada također se nalaze u sažetku opisa svojstava i u uputi o lijeku.
English: For more information about using Lemtrada, see the package leaflet or contact your doctor or pharmacist.
Croatian: Više informacija o primjeni lijeka Lemtrada pročitajte u uputi o lijeku, odnosno obratite se liječniku ili ljekarniku.
English: Treatment should only be started and supervised by a neurologist experienced in treating MS.
Croatian: Liječenje mora započeti i nadzirati neurolog s iskustvom u liječenju multiple skleroze.
English: The company that markets Lemtrada will carry out studies on the safety of the medicine and to assess whether the medicine is used according to the latest recommendations.
Croatian: Tvrtka koja lijek Lemtrada stavlja u promet provest će ispitivanja o sigurnosti lijeka te o tome koristi li se lijek u skladu s najnovijim preporukama.
English: Patients will receive a patient alert card and a guide explaining the risks with the medicine and symptoms of Lemtrada's serious side effects.
Croatian: Bolesnici će dobiti karticu s upozorenjima i vodič s objašnjenjima rizika od lijeka te simptoma najozbiljnijih nuspojava lijeka Lemtrada.
English: With regards to safety, Lemtrada has rare but serious side effects, including disorders of the heart, blood vessels and immune system and measures have been put in place to minimise this risk.1
Croatian: U pogledu sigurnosti, lijek Lemtrada ima rijetke, ali vrlo ozbiljne nuspojave, uključujući poremećaje sa srcem, krvnim žilama i imunosnim sustavom te su uvedene mjere za minimizaciju rizika.1
English: In the first study, the average number of relapses per year in patients given Lemtrada was less than half the number in patients given interferon beta-1a (0.18 versus 0.39), but there was no meaningful effect in terms of progression of disability.
Croatian: U prvom ispitivanju prosječan broj relapsa godišnje u bolesnika koji su primali lijek Lemtrada bio je više od upola manji od broja relapsa u bolesnika koji su primali interferon beta-1a (0,18 nasuprot 0,39), no nije zabilježen značajan učinak u pogledu progresije invaliditeta.
English: When alemtuzumab attaches to the lymphocytes, it causes them to die, and they are replaced by new lymphocytes.
Croatian: Vezivanje alemtuzumaba na limfocite uzrokuje njihovo odumiranje, te se zamjenjuju novim limfocitima.
English: The most common side effects with Lemtrada (which may affect more than 1 in 5 people) are rash, headache, fever and respiratory tract infections (throat and chest infections).
Croatian: Najčešće nuspojave lijeka Lemtrada (koje se mogu javiti u više od 1 na 5 osoba) su osip, glavobolja, vrućica i infekcije dišnih putova (infekcije grla i prsišta).
English: The first study involved previously untreated patients, while the second study involved patients whose disease had relapsed despite treatment.
Croatian: Prvo je ispitivanje obuhvatilo prethodno neliječene bolesnike, a drugo bolesnike u kojih je unatoč liječenju došlo do relapsa bolesti.
English: In the second study, the average number of relapses per year in patients given Lemtrada was half the number in patients given interferon beta-1a (0.26 versus 0.52), and around 13% of patients given Lemtrada had a sustained progression of disability compared with around 21% of patients given interferon beta-1a.
Croatian: U drugom ispitivanju prosječan broj relapsa godišnje u bolesnika koji su primali lijek Lemtrada bio je otprilike upola manji od broja relapsa u bolesnika koji su primali interferon beta-1a (0,26 nasuprot 0,52), a otprilike 13 % bolesnika koji su primali lijek Lemtrada iskusilo je kontinuiranu progresiju invaliditeta u usporedbi s otprilike 21 % bolesnika koji su primali interferon beta-1a.
English: In both studies, Lemtrada was compared with another medicine for multiple sclerosis, interferon beta-1a.
Croatian: U obama ispitivanjima lijek Lemtrada uspoređen je s drugim lijekom za liječenje multiple skleroze, interferonom beta-1a.
English: It should be given in a hospital with access to intensive care, as well as equipment and specialist staff for managing serious reactions and side effects that can occur with Lemtrada.
Croatian: Lijek se primjenjuje u bolnici s pristupom intenzivnoj njezi, opremi i stručnom osoblju za suzbijanje ozbiljnih reakcija i nuspojava koje se mogu javiti s lijekom Lemtrada.
English: Lemtrada must not be used in patients with HIV and in patients with severe infections.
Croatian: Lemtrada se ne smije primjenjivati u bolesnika zaraženih HIV-om ni u bolesnika s teškim infekcijama.
English: It must not be used in patients with uncontrolled hypertension (high blood pressure), patients who have had arterial dissection (tears) of the cervicocephalic arteries (blood vessels in the head and neck), stroke, angina pectoris (pains to the chest, jaw and back, brought on by physical effort and due to problems with the blood flow to the heart) or myocardial infarction (heart attack).
Croatian: Ne smije se primjenjivati u bolesnika s nekontroliranom hipertenzijom (visokim krvnim tlakom), bolesnika s disekcijom (rascjepom) cervikocefalnih aorti (krvnih žila u glavi i vratu), s moždanim udarom, anginom pektoris (bolovima u prsištu, čeljusti i leđima prilikom fizičkog napora zbog problema dotoka krvi u srce) ili s infarktom miokarda (srčanim udarom).
English: In both studies, the main measure of effectiveness was based on the number of relapses the patients had each year and the progression of disability after two years of treatment.
Croatian: U obama ispitivanjima glavno mjerilo učinkovitosti temeljilo se na godišnjem broju relapsa u bolesnika i na progresiji invaliditeta nakon dvije godine liječenja.
English: Lemtrada must not be used in patients with coagulopathy (problems with blood clotting) or in patients who are taking anti-platelet or anti coagulant therapy.
Croatian: Lemtrada se ne smije primjenjivati u bolesnika s koagulopatijom (problemima sa zgrušavanjem krvi) ni u bolesnika koji primaju antitrombocitnu terapiju ili onu protiv zgrušavanja krvi.
English: What benefits of Lemtrada have been shown in studies?
Croatian: Koje su koristi od lijeka Lemtrada utvrđene u ispitivanjima?
English: The most important side effects with Lemtrada are autoimmune conditions (where the body's defence system attacks normal tissue), including thyroid gland disorders, immune thrombocytopenic purpura (a bleeding disorder caused by low blood platelet counts) and kidney damage, as well as low blood cell counts, reactions to the infusion and infections.
Croatian: Najvažnije nuspojave lijeka Lemtrada su autoimune bolesti (kada obrambeni sustav tijela napada zdravo tkivo), uključujući poremećaje štitnjače, imuna trombocitopenična purpura (poremećaj krvarenja uzrokovan niskim brojem trombocita u krvi), oštećenja bubrega, nizak broj krvnih stanica, reakcije na infuziju i infekcije.
English: Patients involved in the two main studies were followed-up for at least four years in an extension study, during which they were given up to two additional doses of Lemtrada, at one-year intervals, if their disease progressed.
Croatian: U okviru produžetka ispitivanja provedeno je kontrolno praćenje bolesnika uključenih u dva glavna ispitivanja u trajanju od najmanje četiri godine, tijekom kojeg su bolesnici u kojih je došlo do progresije bolesti primili dvije dodatne doze lijeka Lemtrada u intervalu od jedne godine.
English: The active substance in Lemtrada, alemtuzumab, is a type of protein called a monoclonal antibody that has been designed to attach to another protein called CD52.
Croatian: Djelatna tvar lijeka Lemtrada, alemtuzumab, vrsta je bjelančevine naziva monoklonsko protutijelo, namijenjeno za vezanje na drugu bjelančevinu naziva CD52.
English: How does Lemtrada work?
Croatian: Kako djeluje Lemtrada?
English: How is Lemtrada used?
Croatian: Kako se Lemtrada primjenjuje?
English: For the full list of side effects of Lemtrada, see the package leaflet.
Croatian: Potpuni popis nuspojava povezanih s lijekom Lemtrada potražite u uputi o lijeku.
English: The medicine must not be used in patients with autoimmune diseases besides MS. For the full list of restrictions, see the package leaflet.
Croatian: Lijek se ne smije primjenjivati u bolesnika s drugim autoimunim bolestima uz multiplu sklerozu.